Comparative Pharmacology
Head-to-head clinical analysis: CALAN SR versus CARDENE SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN SR versus CARDENE SR.
CALAN SR vs CARDENE SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
Oral: 180–240 mg once daily; maximum 480 mg/day.
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker